Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan pharmaceuticals limited - aripiprasool - schizophrenia; bipolar disorder - psühhoeptikumid - aripiprasool mylan pharma on näidustatud skisofreenia raviks täiskasvanutel ja noorukitel vanuses 15 aastat ja vanemad. aripiprasool mylan pharma on näidustatud ravi mõõduka kuni raske maniakaalse episoodi bipolaarne i häire ja ennetamise ning uue maniakaalse episoodi täiskasvanutel, kes on kogenud peamiselt maniakaalsed episoodid ja kelle maniakaalsed episoodid vastas, et aripiprasool ravi. aripiprasool mylan pharma on näidustatud ravi kuni 12 nädala jooksul mõõduka kuni raske maniakaalse episoodi bipolaarne i häire noorukitel vanuses 13 aastat ja vanemad.

Euroopa Liit - eesti - EMA (European Medicines Agency)

zentiva, k.s. - aripiprasool - schizophrenia; bipolar disorder - psühhoeptikumid - aripiprasool zentiva on näidustatud skisofreenia raviks täiskasvanutel ja noorukitel vanuses 15 aastat ja vanemad. aripiprasool zentiva on näidustatud ravi mõõduka kuni raske maniakaalse episoodi bipolaarne i häire ja ennetamise ning uue maniakaalse episoodi täiskasvanutel, kes on kogenud peamiselt maniakaalsed episoodid ja kelle maniakaalsed episoodid vastas, et aripiprasool ravi. aripiprasool zentiva on näidustatud ravi kuni 12 nädala jooksul mõõduka kuni raske maniakaalse episoodi bipolaarne i häire noorukitel vanuses 13 aastat ja vanemad.

Euroopa Liit - eesti - EMA (European Medicines Agency)

belpharma s.a. - tasonermiin - sarkoom - immunostimulants, - beromun on näidatud täiskasvanute lisandina, et operatsioon järgnevate eemaldamist kasvaja nii, et vältida või edasi lükata amputatsioon või palliatiivne olukord, irresectable pehmete kudede sarkoom, jäsemete, kasutatakse koos melphalan kaudu kerge hyperthermic isoleeritud jäseme perfusiooni (ilp).

Euroopa Liit - eesti - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - ibandroonhape - hypercalcemia; breast neoplasms; neoplasm metastasis; fractures, bone - narkootikumid luuhaiguste raviks - bondronat on näidustatud:ennetamine kardiovaskulaarsed sündmused (patoloogilised luumurrud, luude tüsistused nõuavad kiiritusravi või operatsioon) patsientidel, kellel on rinnavähi ja luu metastases;ravi kasvaja põhjustatud hypercalcaemia koos või ilma metastases.

Euroopa Liit - eesti - EMA (European Medicines Agency)

linde healthcare ab - lämmastikoksiidi - hypertension, pulmonary; respiratory insufficiency - muud hingamisteede tooted - inomax koos ventilatoorsed ja muud vajalikud toimeained, mis on märgitud:ravi vastsündinud imikud ≥34 nädalat tiinus koos hüpoksiline hingamispuudulikkus seotud kliiniliste või echocardiographic tõendeid pulmonaalse hüpertensiooniga, et parandada hapnikuga ja vähendada vajadust extracorporeal membrane hapnikuga;osana ravi peri - ja operatsioonijärgse pulmonaalse hüpertensiooniga täiskasvanutel ja vastsündinud imikud imikud ja väikelapsed, lapsed ja noorukid, vanuses 0-17 aastat koos südame operatsiooni, selleks, et valikuliselt vähendada pulmonaalse arteriaalse rõhu ja parandada parema vatsakese funktsiooni ja hapnikuga.

Euroopa Liit - eesti - EMA (European Medicines Agency)

merck sharp & dohme b.v. - pembrolizumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; endometrial neoplasms - antineoplastilised ained - melanomakeytruda as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. keytruda as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with stage iib, iic, or with stage iii melanoma and lymph node involvement who have undergone complete resection. non small cell lung carcinoma (nsclc)keytruda as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum based chemotherapy (for selection criteria, see section 5. keytruda as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express pd l1 with a ≥ 50% tumour proportion score (tps) with no egfr or alk positive tumour mutations. keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non squamous non small cell lung carcinoma in adults whose tumours have no egfr or alk positive mutations. keytruda, in combination with carboplatin and either paclitaxel or nab paclitaxel, is indicated for the first line treatment of metastatic squamous non small cell lung carcinoma in adults. keytruda  as monotherapy is indicated for the treatment of locally advanced or metastatic non small cell lung carcinoma in adults whose tumours express pd l1 with a ≥ 1% tps and who have received at least one prior chemotherapy regimen. patsiendid, kellel on egfr-või kristallimise positiivne kasvaja mutatsioonid peaks ka saanud suunatud ravi enne saanud keytruda. classical hodgkin lymphoma (chl)keytruda as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical hodgkin lymphoma who have failed autologous stem cell transplant (asct) or following at least two prior therapies when asct is not a treatment option. urothelial carcinomakeytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum containing chemotherapy. keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin containing chemotherapy and whose tumours express pd l1 with a combined positive score (cps) ≥ 10. head and neck squamous cell carcinoma (hnscc)keytruda, as monotherapy or in combination with platinum and 5 fluorouracil (5 fu) chemotherapy, is indicated for the first line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express pd l1 with a cps ≥ 1. keytruda as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express pd l1 with a ≥ 50% tps and progressing on or after platinum containing chemotherapy. renal cell carcinoma (rcc)keytruda, in combination with axitinib, is indicated for the first line treatment of advanced renal cell carcinoma in adults. keytruda  as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions (for selection criteria, please see section 5. microsatellite instability high (msi-h) or mismatch repair deficient (dmmr) cancerscolorectal cancer (crc)keytruda as monotherapy is indicated for theadults with msi-h or dmmr colorectal cancer in the following settings:first line treatment of metastatic microsatellite instability high (msi h) or mismatch repair deficient (dmmr) colorectal cancer in adults;treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine based combination therapy.  non-colorectal cancerskeytruda as monotherapy is indicated for the treatment of the following msi h or dmmr tumours in adults with:advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation;unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. oesophageal carcinomakeytruda, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or her-2 negative gastroesophageal junction adenocarcinoma, in adults whose tumours express pd l1 with a cps ≥ 10. triple negative breast cancer (tnbc)keytruda, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence. keytruda, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express pd l1 with a cps ≥ 10 and who have not received prior chemotherapy for metastatic disease. endometrial carcinoma (ec)keytruda, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation. cervical cancerkeytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express pd l1 with a cps ≥ 1. gastric or gastro-oesophageal junction (gej) adenocarcinomakeytruda, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic her2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express pd-l1 with a cps ≥ 1.

Euroopa Liit - eesti - EMA (European Medicines Agency)

teva b.v.  - sildenafiil - erektiilne düsfunktsioon - erektsioonihäirete ravimid - erektsioonihäire on võimetus saavutada või säilitada peenise erektsioon, mis on piisav rahuldava suguelu meeste raviks. selleks, et sildenafiili teva, et olla efektiivne, on vajalik seksuaalne stimulatsioon.

Euroopa Liit - eesti - EMA (European Medicines Agency)

roche registration gmbh  - pertuzumab - rinnanäärmed - antineoplastic agents, monoclonal antibodies - metastaatilise rinnavähi:perjeta on näidustatud kasutamiseks koos trastuzumab ja docetaxel täiskasvanud patsientidel, kellel her2-positiivse metastaatilise või lokaalselt korduva unresectable rinnavähk, kes ei ole saanud eelmise anti-her2 ravi või keemiaravi oma metastaatilise haiguse. neoadjuvant ravi rinnavähi:perjeta on näidustatud kasutamiseks koos trastuzumab ja kemoteraapia jaoks neoadjuvant ravi täiskasvanud patsientidel, kellel her2-positiivne, lokaalselt kaugelearenenud, põletikuline või varajases staadiumis rinnavähi puhul on suur risk kordumise kohta.

Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi winthrop industrie - aflibercept - kolorektaalne kasvaja - antineoplastilised ained - metastaatilise kolorektaalse vähi (mcrc) ravi.

Euroopa Liit - eesti - EMA (European Medicines Agency)

actavis group ptc ehf   - zoledroonhappe monohüdraat - luumurrud - narkootikumid luuhaiguste raviks - patsientidel luustikuga seotud luukude haarava (patoloogilised luumurrud, seljaaju kompressioon, kiiritusravi või operatsioon luu või kasvajast). ravi täiskasvanud patsientidel, kellel kasvaja põhjustatud hypercalcaemia.